Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 4, 2007, Pages 549-558

  Comté, Laetitia ^a   Vrijens, Bernard ^a,b   Tousset, Eric ^b   Gérard, Paul ^a   Urquhart, John ^b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Pharmionic Systems Ltd   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Compliance HIV; Drug dosing regimens; Once daily dosing; Pharmacodynamics; Pharmacokinetics; PI concentration in plasma; Systems therapeutics; Time history of drug intake; Twice daily dosing

Indexed keywords

LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY;

ALGORITHMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; ODDS RATIO; PATIENT COMPLIANCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447116915     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-007-9058-0     Document Type: Article

References (13)

1. Moyle G (2002) The appt-1 study: assessing patients preferred treatments. Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection. November 17-21, Glasgow, Scotland, Abstract p 90
2. Hughes D (2006). Less is more: medicines that require less frequent administration improve adherence, but are they better?. Pharmacoeconomics 24(3): 211-213
3. Claxton AJ, Cramer J and Pierce C (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8): 1296-1310
4. Vrijens B and Urquhart J (2005). Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 55(5): 616-627
5. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S and Urquhart J (2005). Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 45(4): 461-467
6. Vrijens B, Tousset E, Gaillard P-A, Metry JM and Urquhart J (2005). Major features of dose omissions in 87 ambulatory drug trials. Clin Pharmacol Ther 77(2): 99
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM and Singh N (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30
8. Paterson DL, Potoski B and Capitano B (2002). Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 31(Suppl 3): S103-S106
9. Vrijens B and Goetghebeur E (1997). Comparing compliance patterns between randomized treatments. Control Clin Trials 18(3): 187-203
10. Bertz R, Renz C, Foit C, Swerdlow J, Ye X, Jasinsky O, Hsu A, Granneman GR, Sun E (2001) Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food. Second International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands
11. Kaletra® Prescribing Information, Abbott Laboratories, January (2002)
12. Urquhart J and Vrijens B (2005). New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. EJHP 5: 103-106
13. http://www.labcorp.com/pdf/TheraSure_LabFacet_1451.pdf